Year : 1983 | Volume
: 31 | Issue : 7 | Page : 992--994
Clinical evaluation of tromaril as an anti-inflammatory agent in ophthalmic practice
MV Albal, UR Pradhan, AG Chandorkar
Department of Ophthalmology and Department of Pharmacology, Dr. VM Medical College, Solapur, India
A G Chandorkar
Department of Pharmacology, Dr. V.M. Medical College, Solapur 413 003. Maharashtra State
|How to cite this article:|
Albal M V, Pradhan U R, Chandorkar A G. Clinical evaluation of tromaril as an anti-inflammatory agent in ophthalmic practice.Indian J Ophthalmol 1983;31:992-994
|How to cite this URL:|
Albal M V, Pradhan U R, Chandorkar A G. Clinical evaluation of tromaril as an anti-inflammatory agent in ophthalmic practice. Indian J Ophthalmol [serial online] 1983 [cited 2021 Sep 21 ];31:992-994
Available from: https://www.ijo.in/text.asp?1983/31/7/992/29726
Tromaril is an anthranilic acid derivative with potent anti-inflammatory, anti-arthritic, analgesic and antipyretic actions. It has additional unique property of anti-platelet aggregation activity, without disturbing any other blood coagulation factors. It also differs from other non-steroidal anti-inflammatory agents like indomethacin, in producing diuresis and natriuresis.
Tormaril is very effective in the treatment of acute swellings due to trauma or postoperative tissue injury. In case of infections leading to inflammation of various tissues. Tromaril by its anti-inflammatory and anti-edema property forms a very useful adjuvant to chemotherapy and reduces the pain and discomfort of the patient. Therefore, it was decided to evaluate the therapeutic efficacy and tolerability of Tromaril, and to compare its anti-inflammatory and analgesic property with that of oxyphenbutazone in ophthalmic inflammatory conditions.
MATERIAL AND METHODS
One hundred and twenty patients with either inflammatory or ulcerative conditions or operated for cataracts, glaucoma or squint [Table 1] were allotted serialy to either group in an opern trial. Tromaril or oxyphenbutazone was administered in a does of 1200 mg per day and 300 mg per day respectively.
Clinical assessment was done both subjectively and objectively before and after treatment. The parameters for clinical evaluation like pain, oedema, tenderness, congestions, were graded as: severe as 4, moderate to severe as 3, moderate as 2, mild as 1 and nil as 0.
Side effects were graded as severe - 3, moderate - 2, mild - 1 or nil - 0, while patients acceptance was scored as excellent --- 4, good - 3, fair - 2 and poor - 1. An over all assessment was made to decide the effieacy of the drug and graded as : highly effective as - 4, effective as - 3, moderately effective as - 2 and ineffective as - 1.
Pain and tenderness was reduced by second day with from severe or from maderate to severe, to mild or moderate degree. concommitant significant reduction in congestion and swelling. By the end of fourth day no pain Tendernessor was seen and sign of inflammation subsided in 83% patients treated with tromaril and in 80% patients trated with oxyphenbutazone. By the sixth day about 98% and 93% patient." on Tromaril and oxyphenbutazone respectively were clinically free from inflammation [Table 2]. Very few patients needed any adjuvant antibiotic therapy. Patients acceptance was excellent in most of the cases and no side effects were seen either with tromaril or oxyphenbutazone. Both the druges were highly effective (Tromaril - 83°6, and oxphenbutazone - 70%) and no significant difference was seen in over all essessment [Table 3].
Tromaril, in a double blind trial in episiotomy patients showed a highly significant anti-inflammatory and analgesic effect with the same degree of therapeutic efficacy and tolerability as oxyphenbutazone,,. sub Similar results have been obtained in dental surgery. Our results in ophthalmic patients are also in confirmity with the above.
The role of prostaglandin in inflammation is well known. Tromaril is shown to inhibit the prostaglandin synthetase and hence the likely mechanisms of its anti-inflammatory activity could be prostaglandin synthetase inhibition, leading to decreased prostaglandin synthesis and release.
Tromaril is devoid of gastric irritation or other side effects and is well accepted by the patient. Like oxyphenbutazone it does not interact with anticoagulants or oral anfidiabetic agents, so its use would be safer in patients on above drug regimens who develop ulcerative or inflammatory conditions in the eye.
Tromaril an anti-inflammatory, analgesic and antipyretic agent was evaluated by an open trial in ophthalmic postoperative, ulcerative and inflammatory conditions. It was found to be as effective as oxyphenbutazone and no took effects were seen.
We are grateful to Dr. J.H. Balwani, Medical Adviser, Unichem Lab. Pvt. Ltd. for the supply of drugs and to the Dean, Dr. V.M. Medical College, Solapur for facilities.
|1||Lokabai, N., and Reddy, D., 1980, Jr. Asso. Phys. Ind., (Special suppl.), 28:118.|
|2||Punjabi, J., Krishna, U.R., Paul, T. and Sheth U.K., 1980 Jr. Asso. Phys. Ind., (Special Supply), 28:115.|
|3||Vacharajani, G.M., Gupta, K.C., Paul, T., and Sheth, U.K., 1980, Jr. Asso. Hpys. Ind. (special Supply), 28:127.|
|4||Chitra,A.R, and Hussain, T., 1980 Jr. Asso. Phys.Ind. (Special Suppl), 28:129.|
|5||Kshirsagar, NA, Athanikar, N. Jha, A, and Sheth, U.K, .1980 Jr. Asso. Phys. Ind., (Special Suppl), 28:39.|